title: Secondary prevention of cardiovascular disease with vorapaxar: a new era of 3-drug antiplatelet therapy?
authors.affiliation: Division of Cardiology, University of Colorado School of Medicine, Aurora2Denver Health Medical Center, Denver, Colorado3Colorado Prevention Center, Aurora.
authors.forename: Mori J
authors.initials: MJ
authors.lastname: Krantz
authors.affiliation: Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California5David Geffen School of Medicine at the University of California, Los Angeles.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kaul
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D055502:Secondary Prevention / Q000379:methods*
chemical_list: D007783:Lactones; D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; C530299:vorapaxar